Cowen and Company reaffirmed their hold rating on shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) in a report published on Thursday.

“Sunesis reported Q3 Net loss of $9.9MM and pro forma September 30 cash of.”,” the firm’s analyst commented.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, July 11th. Cantor Fitzgerald restated a hold rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Thursday, July 27th. Finally, ValuEngine cut Sunesis Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, September 1st.

Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up $0.35 on Thursday, reaching $3.00. The company’s stock had a trading volume of 371,812 shares, compared to its average volume of 309,153. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the business earned ($0.62) earnings per share. equities analysts anticipate that Sunesis Pharmaceuticals will post -1.66 earnings per share for the current fiscal year.

WARNING: “Sunesis Pharmaceuticals, Inc. (SNSS) Earns Hold Rating from Cowen and Company” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/sunesis-pharmaceuticals-inc-snss-earns-hold-rating-from-cowen-and-company/1681456.html.

In related news, Director Dayton Misfeldt purchased 400,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average cost of $2.00 per share, with a total value of $800,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 10.21% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Wells Fargo & Company MN lifted its stake in Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Sunesis Pharmaceuticals in the 2nd quarter valued at about $208,000. Renaissance Technologies LLC lifted its stake in Sunesis Pharmaceuticals by 1.1% in the 1st quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after buying an additional 1,230 shares in the last quarter. Sphera Funds Management LTD. lifted its stake in Sunesis Pharmaceuticals by 54.6% in the 2nd quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares in the last quarter. 57.56% of the stock is currently owned by hedge funds and other institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.